Wachtfogel Y T, DeLa Cadena R A, Kunapuli S P, Rick L, Miller M, Schultze R L, Altieri D C, Edgington T S, Colman R W
Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
J Biol Chem. 1994 Jul 29;269(30):19307-12.
High molecular weight kininogen (HK) binds specifically, saturably, and reversibly to neutrophils and also reciprocally inhibits the binding of fibrinogen to neutrophils. Since fibrinogen binds to the leukocyte integrin CD11b/18 (Mac-1, alpha M beta 2), we investigated whether HK bound to Mac-1 and whether the binding site was similar to that for factor X. We also examined whether one or both chains of cleaved HK (HKa) were involved. Two monoclonal antibodies, 2B5 (0.29 microM) to HK heavy chain domains 2 (D2) and 3 (D3), and C11C1 (0.26 microM) to HK light chain domain 5 (D5), inhibited by 99 and 93% the binding, respectively, of 125I-HK (8.3 nM) to neutrophils. To minimize steric hindrance, we further demonstrated that the Fab' fragments of 2B5 and C11C1 were able to inhibit the binding of this ligand to virtually the same extent as the intact antibody, indicating that, as in binding of HK to platelets and endothelial cells, both chains are involved. To directly demonstrate the involvement of each chain, we showed that the reduced alkylated light chain derived from HK and low molecular weight kininogen, which contains the same heavy chain as HK, each markedly inhibited the binding of HK to neutrophils. We localized the domain responsible for the binding in each chain by showing that recombinant D3 and D5 decreased the binding of HK to neutrophils. To define the receptor for HK, we employed three monoclonal antibodies to Mac-1: OKM1 and OKM10 to epitopes on the alpha M subunit and IB4 to an epitope on the beta 2 chain. OKM1, which can inhibit fibrinogen binding to neutrophils, inhibited HK binding by 79%, whereas the other antibodies inhibited HK binding less than 25%. Coagulation factor X also binds to Mac-1 on monocytes at a similar site to C3bi. Synthetic peptides which define noncontiguous surface loops in factor X that interact with Mac-1, failed to inhibit 125I-HK binding to neutrophils. We conclude that HK binds, via domains on its heavy chain, D3, and light chain, D5, to Mac-1 on the neutrophil surface, and HK occupies a site overlapping with fibrinogen and different from factor X.
高分子量激肽原(HK)能特异性、饱和性且可逆地与中性粒细胞结合,并且能相互抑制纤维蛋白原与中性粒细胞的结合。由于纤维蛋白原与白细胞整合素CD11b/18(Mac-1,αMβ2)结合,我们研究了HK是否与Mac-1结合以及其结合位点是否与因子X的结合位点相似。我们还研究了裂解后的HK(HKa)的一条链还是两条链参与其中。两种单克隆抗体,针对HK重链结构域2(D2)和3(D3)的2B5(0.29微摩尔)以及针对HK轻链结构域5(D5)的C11C1(0.26微摩尔),分别抑制了125I-HK(8.3纳摩尔)与中性粒细胞99%和93%的结合。为了尽量减少空间位阻,我们进一步证明2B5和C11C1的Fab'片段能够与完整抗体几乎以相同程度抑制该配体的结合,这表明,如同HK与血小板和内皮细胞的结合一样,两条链都参与其中。为了直接证明每条链的参与情况,我们表明,源自HK和低分子量激肽原的还原烷基化轻链,其重链与HK相同,各自都能显著抑制HK与中性粒细胞的结合。通过显示重组D3和D5降低了HK与中性粒细胞的结合,我们确定了每条链中负责结合的结构域。为了确定HK的受体,我们使用了三种针对Mac-1的单克隆抗体:针对αM亚基表位的OKM1和OKM10以及针对β2链表位的IB4。能抑制纤维蛋白原与中性粒细胞结合的OKM1抑制HK结合达79%,而其他抗体抑制HK结合不到25%。凝血因子X也在与C3bi相似的位点与单核细胞上的Mac-1结合。确定了与Mac-1相互作用的因子X中不连续表面环的合成肽,未能抑制125I-HK与中性粒细胞的结合。我们得出结论,HK通过其重链上的结构域D3和轻链上的结构域D5与中性粒细胞表面的Mac-1结合,并且HK占据了与纤维蛋白原重叠且不同于因子X的位点。